nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—CYP3A4—prostate cancer	0.129	0.505	CbGaD
Pomalidomide—PTGS2—prostate cancer	0.126	0.495	CbGaD
Pomalidomide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0346	0.084	CbGbCtD
Pomalidomide—CYP1A2—Flutamide—prostate cancer	0.0288	0.0698	CbGbCtD
Pomalidomide—ABCB1—Estramustine—prostate cancer	0.0282	0.0684	CbGbCtD
Pomalidomide—CYP1A2—Estrone—prostate cancer	0.0208	0.0504	CbGbCtD
Pomalidomide—PTGS2—Etoposide—prostate cancer	0.0207	0.0501	CbGbCtD
Pomalidomide—ABCB1—Cabazitaxel—prostate cancer	0.0186	0.0451	CbGbCtD
Pomalidomide—CYP3A4—Bicalutamide—prostate cancer	0.0182	0.0441	CbGbCtD
Pomalidomide—ABCB1—Estrone—prostate cancer	0.0182	0.0441	CbGbCtD
Pomalidomide—CYP3A4—Estramustine—prostate cancer	0.0169	0.041	CbGbCtD
Pomalidomide—ABCB1—Ethinyl Estradiol—prostate cancer	0.0162	0.0393	CbGbCtD
Pomalidomide—CYP3A4—Abiraterone—prostate cancer	0.0151	0.0366	CbGbCtD
Pomalidomide—CYP3A4—Flutamide—prostate cancer	0.0151	0.0366	CbGbCtD
Pomalidomide—CYP1A2—Conjugated Estrogens—prostate cancer	0.0136	0.033	CbGbCtD
Pomalidomide—CYP1A2—Estradiol—prostate cancer	0.0119	0.029	CbGbCtD
Pomalidomide—ABCB1—Conjugated Estrogens—prostate cancer	0.0119	0.0289	CbGbCtD
Pomalidomide—CYP3A4—Cabazitaxel—prostate cancer	0.0111	0.027	CbGbCtD
Pomalidomide—CYP3A4—Estrone—prostate cancer	0.0109	0.0264	CbGbCtD
Pomalidomide—ABCB1—Mitoxantrone—prostate cancer	0.0108	0.0262	CbGbCtD
Pomalidomide—ABCB1—Estradiol—prostate cancer	0.0104	0.0253	CbGbCtD
Pomalidomide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00971	0.0236	CbGbCtD
Pomalidomide—ABCB1—Prednisone—prostate cancer	0.00898	0.0218	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—prostate cancer	0.0078	0.0189	CbGbCtD
Pomalidomide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00712	0.0173	CbGbCtD
Pomalidomide—ABCB1—Etoposide—prostate cancer	0.00682	0.0165	CbGbCtD
Pomalidomide—CYP3A4—Mitoxantrone—prostate cancer	0.00648	0.0157	CbGbCtD
Pomalidomide—CYP3A4—Estradiol—prostate cancer	0.00626	0.0152	CbGbCtD
Pomalidomide—ABCB1—Docetaxel—prostate cancer	0.00624	0.0151	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—prostate cancer	0.00538	0.0131	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—prostate cancer	0.00465	0.0113	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—prostate cancer	0.00408	0.00991	CbGbCtD
Pomalidomide—CYP3A4—Docetaxel—prostate cancer	0.00374	0.00907	CbGbCtD
Pomalidomide—Lenalidomide—TNFSF11—prostate cancer	0.00292	0.512	CrCbGaD
Pomalidomide—CRBN—prostate gland—prostate cancer	0.00281	0.108	CbGeAlD
Pomalidomide—CYP3A4—Doxorubicin—prostate cancer	0.00279	0.00676	CbGbCtD
Pomalidomide—CYP1A2—urine—prostate cancer	0.00258	0.0987	CbGeAlD
Pomalidomide—CRBN—seminal vesicle—prostate cancer	0.00238	0.0911	CbGeAlD
Pomalidomide—CRBN—renal system—prostate cancer	0.00192	0.0734	CbGeAlD
Pomalidomide—CRBN—urethra—prostate cancer	0.00188	0.0721	CbGeAlD
Pomalidomide—TNF—lymph node—prostate cancer	0.00188	0.072	CbGeAlD
Pomalidomide—CYP3A4—urine—prostate cancer	0.00187	0.0714	CbGeAlD
Pomalidomide—CRBN—bone marrow—prostate cancer	0.00145	0.0555	CbGeAlD
Pomalidomide—CRBN—testis—prostate cancer	0.00124	0.0475	CbGeAlD
Pomalidomide—Thalidomide—FGFR2—prostate cancer	0.00111	0.194	CrCbGaD
Pomalidomide—CRBN—lymph node—prostate cancer	0.000899	0.0344	CbGeAlD
Pomalidomide—PTGS2—prostate gland—prostate cancer	0.000766	0.0293	CbGeAlD
Pomalidomide—PTGS2—seminal vesicle—prostate cancer	0.000648	0.0248	CbGeAlD
Pomalidomide—CYP1A2—renal system—prostate cancer	0.00063	0.0241	CbGeAlD
Pomalidomide—PTGS2—epithelium—prostate cancer	0.000563	0.0216	CbGeAlD
Pomalidomide—PTGS2—renal system—prostate cancer	0.000522	0.02	CbGeAlD
Pomalidomide—PTGS2—urethra—prostate cancer	0.000513	0.0196	CbGeAlD
Pomalidomide—ABCB1—prostate gland—prostate cancer	0.000474	0.0181	CbGeAlD
Pomalidomide—CYP3A4—renal system—prostate cancer	0.000456	0.0175	CbGeAlD
Pomalidomide—Thalidomide—CYP3A5—prostate cancer	0.000401	0.0703	CrCbGaD
Pomalidomide—ABCB1—seminal vesicle—prostate cancer	0.000401	0.0153	CbGeAlD
Pomalidomide—PTGS2—bone marrow—prostate cancer	0.000395	0.0151	CbGeAlD
Pomalidomide—ABCB1—epithelium—prostate cancer	0.000348	0.0133	CbGeAlD
Pomalidomide—ABCB1—renal system—prostate cancer	0.000323	0.0124	CbGeAlD
Pomalidomide—ABCB1—urethra—prostate cancer	0.000317	0.0122	CbGeAlD
Pomalidomide—Lenalidomide—PTGS2—prostate cancer	0.000284	0.0497	CrCbGaD
Pomalidomide—Thalidomide—CYP2E1—prostate cancer	0.000276	0.0483	CrCbGaD
Pomalidomide—Thalidomide—CYP2C19—prostate cancer	0.000273	0.0478	CrCbGaD
Pomalidomide—Thalidomide—CYP1A1—prostate cancer	0.000272	0.0477	CrCbGaD
Pomalidomide—PTGS2—lymph node—prostate cancer	0.000245	0.00937	CbGeAlD
Pomalidomide—ABCB1—bone marrow—prostate cancer	0.000244	0.00935	CbGeAlD
Pomalidomide—ABCB1—testis—prostate cancer	0.000209	0.00799	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—prostate cancer	0.00017	0.0298	CrCbGaD
Pomalidomide—ABCB1—lymph node—prostate cancer	0.000151	0.00579	CbGeAlD
Pomalidomide—Nasopharyngitis—Doxorubicin—prostate cancer	6.17e-05	0.00033	CcSEcCtD
Pomalidomide—Anaemia—Docetaxel—prostate cancer	6.15e-05	0.000329	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—prostate cancer	6.12e-05	0.000328	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—prostate cancer	6.08e-05	0.000326	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—prostate cancer	6.08e-05	0.000326	CcSEcCtD
Pomalidomide—Asthenia—Estradiol—prostate cancer	6.05e-05	0.000324	CcSEcCtD
Pomalidomide—Tremor—Capecitabine—prostate cancer	6.04e-05	0.000323	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—prostate cancer	6.03e-05	0.000322	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—prostate cancer	5.99e-05	0.000321	CcSEcCtD
Pomalidomide—Angiopathy—Prednisone—prostate cancer	5.98e-05	0.00032	CcSEcCtD
Pomalidomide—Pruritus—Estradiol—prostate cancer	5.97e-05	0.000319	CcSEcCtD
Pomalidomide—Leukopenia—Docetaxel—prostate cancer	5.96e-05	0.000319	CcSEcCtD
Pomalidomide—Anaemia—Capecitabine—prostate cancer	5.96e-05	0.000319	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—prostate cancer	5.86e-05	0.000314	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—prostate cancer	5.83e-05	0.000312	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—prostate cancer	5.83e-05	0.000312	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—prostate cancer	5.81e-05	0.000311	CcSEcCtD
Pomalidomide—Cough—Docetaxel—prostate cancer	5.81e-05	0.000311	CcSEcCtD
Pomalidomide—Vertigo—Capecitabine—prostate cancer	5.79e-05	0.00031	CcSEcCtD
Pomalidomide—Hypersensitivity—Mitoxantrone—prostate cancer	5.79e-05	0.00031	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—prostate cancer	5.78e-05	0.000309	CcSEcCtD
Pomalidomide—Mental disorder—Prednisone—prostate cancer	5.78e-05	0.000309	CcSEcCtD
Pomalidomide—Diarrhoea—Estradiol—prostate cancer	5.77e-05	0.000309	CcSEcCtD
Pomalidomide—Leukopenia—Capecitabine—prostate cancer	5.77e-05	0.000309	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—prostate cancer	5.75e-05	0.000308	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—prostate cancer	5.75e-05	0.000308	CcSEcCtD
Pomalidomide—Malnutrition—Prednisone—prostate cancer	5.74e-05	0.000307	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—prostate cancer	5.73e-05	0.000307	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—prostate cancer	5.68e-05	0.000304	CcSEcCtD
Pomalidomide—Arthralgia—Docetaxel—prostate cancer	5.67e-05	0.000303	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—prostate cancer	5.66e-05	0.000303	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—prostate cancer	5.65e-05	0.000302	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—prostate cancer	5.64e-05	0.000302	CcSEcCtD
Pomalidomide—Asthenia—Mitoxantrone—prostate cancer	5.64e-05	0.000302	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—prostate cancer	5.64e-05	0.000302	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—prostate cancer	5.63e-05	0.000301	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.63e-05	0.000301	CcSEcCtD
Pomalidomide—Cough—Capecitabine—prostate cancer	5.62e-05	0.000301	CcSEcCtD
Pomalidomide—Pain—Etoposide—prostate cancer	5.59e-05	0.000299	CcSEcCtD
Pomalidomide—Constipation—Etoposide—prostate cancer	5.59e-05	0.000299	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—prostate cancer	5.59e-05	0.000299	CcSEcCtD
Pomalidomide—Dizziness—Estradiol—prostate cancer	5.58e-05	0.000299	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—prostate cancer	5.58e-05	0.000298	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—prostate cancer	5.54e-05	0.000297	CcSEcCtD
Pomalidomide—Arthralgia—Capecitabine—prostate cancer	5.49e-05	0.000294	CcSEcCtD
Pomalidomide—Confusional state—Docetaxel—prostate cancer	5.48e-05	0.000293	CcSEcCtD
Pomalidomide—Anxiety—Capecitabine—prostate cancer	5.47e-05	0.000293	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.45e-05	0.000292	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—prostate cancer	5.43e-05	0.000291	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—prostate cancer	5.43e-05	0.00029	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—prostate cancer	5.42e-05	0.00029	CcSEcCtD
Pomalidomide—Infection—Docetaxel—prostate cancer	5.4e-05	0.000289	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—prostate cancer	5.39e-05	0.000289	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—prostate cancer	5.39e-05	0.000288	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—prostate cancer	5.38e-05	0.000288	CcSEcCtD
Pomalidomide—Diarrhoea—Mitoxantrone—prostate cancer	5.38e-05	0.000288	CcSEcCtD
Pomalidomide—Vomiting—Estradiol—prostate cancer	5.36e-05	0.000287	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—prostate cancer	5.35e-05	0.000286	CcSEcCtD
Pomalidomide—Nervous system disorder—Docetaxel—prostate cancer	5.33e-05	0.000285	CcSEcCtD
Pomalidomide—Thrombocytopenia—Docetaxel—prostate cancer	5.32e-05	0.000285	CcSEcCtD
Pomalidomide—Rash—Estradiol—prostate cancer	5.32e-05	0.000285	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—prostate cancer	5.32e-05	0.000285	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—prostate cancer	5.32e-05	0.000285	CcSEcCtD
Pomalidomide—Dermatitis—Estradiol—prostate cancer	5.31e-05	0.000284	CcSEcCtD
Pomalidomide—Anaemia—Prednisone—prostate cancer	5.31e-05	0.000284	CcSEcCtD
Pomalidomide—Confusional state—Capecitabine—prostate cancer	5.3e-05	0.000284	CcSEcCtD
Pomalidomide—Headache—Estradiol—prostate cancer	5.28e-05	0.000283	CcSEcCtD
Pomalidomide—Skin disorder—Docetaxel—prostate cancer	5.28e-05	0.000282	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—prostate cancer	5.23e-05	0.00028	CcSEcCtD
Pomalidomide—Infection—Capecitabine—prostate cancer	5.23e-05	0.00028	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—prostate cancer	5.21e-05	0.000279	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—prostate cancer	5.17e-05	0.000277	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—prostate cancer	5.17e-05	0.000277	CcSEcCtD
Pomalidomide—Nervous system disorder—Capecitabine—prostate cancer	5.16e-05	0.000276	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—prostate cancer	5.16e-05	0.000276	CcSEcCtD
Pomalidomide—Thrombocytopenia—Capecitabine—prostate cancer	5.15e-05	0.000276	CcSEcCtD
Pomalidomide—Skin disorder—Capecitabine—prostate cancer	5.11e-05	0.000273	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—prostate cancer	5.09e-05	0.000273	CcSEcCtD
Pomalidomide—Hyperhidrosis—Capecitabine—prostate cancer	5.09e-05	0.000272	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—prostate cancer	5.08e-05	0.000272	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—prostate cancer	5.07e-05	0.000271	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—prostate cancer	5.06e-05	0.000271	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—prostate cancer	5.03e-05	0.000269	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—prostate cancer	5.01e-05	0.000268	CcSEcCtD
Pomalidomide—Nausea—Estradiol—prostate cancer	5.01e-05	0.000268	CcSEcCtD
Pomalidomide—Vomiting—Mitoxantrone—prostate cancer	5e-05	0.000267	CcSEcCtD
Pomalidomide—Rash—Mitoxantrone—prostate cancer	4.96e-05	0.000265	CcSEcCtD
Pomalidomide—Dermatitis—Mitoxantrone—prostate cancer	4.95e-05	0.000265	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.95e-05	0.000265	CcSEcCtD
Pomalidomide—Headache—Mitoxantrone—prostate cancer	4.92e-05	0.000264	CcSEcCtD
Pomalidomide—Insomnia—Docetaxel—prostate cancer	4.91e-05	0.000263	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—prostate cancer	4.89e-05	0.000262	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—prostate cancer	4.87e-05	0.000261	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.85e-05	0.00026	CcSEcCtD
Pomalidomide—Dyspnoea—Docetaxel—prostate cancer	4.84e-05	0.000259	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—prostate cancer	4.82e-05	0.000258	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.79e-05	0.000256	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—prostate cancer	4.79e-05	0.000256	CcSEcCtD
Pomalidomide—Insomnia—Capecitabine—prostate cancer	4.76e-05	0.000255	CcSEcCtD
Pomalidomide—Decreased appetite—Docetaxel—prostate cancer	4.72e-05	0.000253	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—prostate cancer	4.71e-05	0.000252	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—prostate cancer	4.7e-05	0.000252	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Docetaxel—prostate cancer	4.69e-05	0.000251	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—prostate cancer	4.69e-05	0.000251	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—prostate cancer	4.69e-05	0.000251	CcSEcCtD
Pomalidomide—Dyspnoea—Capecitabine—prostate cancer	4.69e-05	0.000251	CcSEcCtD
Pomalidomide—Fatigue—Docetaxel—prostate cancer	4.68e-05	0.000251	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—prostate cancer	4.68e-05	0.00025	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—prostate cancer	4.68e-05	0.00025	CcSEcCtD
Pomalidomide—Nausea—Mitoxantrone—prostate cancer	4.67e-05	0.00025	CcSEcCtD
Pomalidomide—Infection—Prednisone—prostate cancer	4.66e-05	0.000249	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—prostate cancer	4.65e-05	0.000249	CcSEcCtD
Pomalidomide—Constipation—Docetaxel—prostate cancer	4.65e-05	0.000249	CcSEcCtD
Pomalidomide—Pain—Docetaxel—prostate cancer	4.65e-05	0.000249	CcSEcCtD
Pomalidomide—Chills—Epirubicin—prostate cancer	4.63e-05	0.000248	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—prostate cancer	4.63e-05	0.000248	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—prostate cancer	4.6e-05	0.000246	CcSEcCtD
Pomalidomide—Decreased appetite—Capecitabine—prostate cancer	4.57e-05	0.000245	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—prostate cancer	4.55e-05	0.000244	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Capecitabine—prostate cancer	4.54e-05	0.000243	CcSEcCtD
Pomalidomide—Fatigue—Capecitabine—prostate cancer	4.54e-05	0.000243	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—prostate cancer	4.53e-05	0.000242	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—prostate cancer	4.52e-05	0.000242	CcSEcCtD
Pomalidomide—Pain—Capecitabine—prostate cancer	4.5e-05	0.000241	CcSEcCtD
Pomalidomide—Constipation—Capecitabine—prostate cancer	4.5e-05	0.000241	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—prostate cancer	4.49e-05	0.00024	CcSEcCtD
Pomalidomide—Feeling abnormal—Docetaxel—prostate cancer	4.48e-05	0.00024	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—prostate cancer	4.47e-05	0.000239	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—prostate cancer	4.43e-05	0.000237	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—prostate cancer	4.34e-05	0.000232	CcSEcCtD
Pomalidomide—Feeling abnormal—Capecitabine—prostate cancer	4.33e-05	0.000232	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—prostate cancer	4.33e-05	0.000232	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—prostate cancer	4.32e-05	0.000231	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—prostate cancer	4.32e-05	0.000231	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—prostate cancer	4.3e-05	0.00023	CcSEcCtD
Pomalidomide—Body temperature increased—Docetaxel—prostate cancer	4.3e-05	0.00023	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—prostate cancer	4.28e-05	0.000229	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—prostate cancer	4.27e-05	0.000228	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—prostate cancer	4.24e-05	0.000227	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—prostate cancer	4.18e-05	0.000224	CcSEcCtD
Pomalidomide—Body temperature increased—Capecitabine—prostate cancer	4.16e-05	0.000223	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—prostate cancer	4.16e-05	0.000222	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—prostate cancer	4.15e-05	0.000222	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—prostate cancer	4.15e-05	0.000222	CcSEcCtD
Pomalidomide—Rash—Etoposide—prostate cancer	4.12e-05	0.000221	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—prostate cancer	4.12e-05	0.00022	CcSEcCtD
Pomalidomide—Headache—Etoposide—prostate cancer	4.1e-05	0.000219	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—prostate cancer	4.07e-05	0.000218	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—prostate cancer	4.04e-05	0.000216	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—prostate cancer	4.03e-05	0.000216	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—prostate cancer	4.02e-05	0.000215	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—prostate cancer	4.02e-05	0.000215	CcSEcCtD
Pomalidomide—Constipation—Prednisone—prostate cancer	4.01e-05	0.000214	CcSEcCtD
Pomalidomide—Hypersensitivity—Docetaxel—prostate cancer	4e-05	0.000214	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—prostate cancer	3.99e-05	0.000214	CcSEcCtD
Pomalidomide—Cough—Epirubicin—prostate cancer	3.92e-05	0.00021	CcSEcCtD
Pomalidomide—Asthenia—Docetaxel—prostate cancer	3.9e-05	0.000209	CcSEcCtD
Pomalidomide—Nausea—Etoposide—prostate cancer	3.88e-05	0.000208	CcSEcCtD
Pomalidomide—Hypersensitivity—Capecitabine—prostate cancer	3.88e-05	0.000207	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisone—prostate cancer	3.86e-05	0.000207	CcSEcCtD
Pomalidomide—Pruritus—Docetaxel—prostate cancer	3.84e-05	0.000206	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—prostate cancer	3.84e-05	0.000206	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—prostate cancer	3.82e-05	0.000205	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—prostate cancer	3.81e-05	0.000204	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.8e-05	0.000203	CcSEcCtD
Pomalidomide—Asthenia—Capecitabine—prostate cancer	3.77e-05	0.000202	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—prostate cancer	3.73e-05	0.0002	CcSEcCtD
Pomalidomide—Pruritus—Capecitabine—prostate cancer	3.72e-05	0.000199	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—prostate cancer	3.72e-05	0.000199	CcSEcCtD
Pomalidomide—Diarrhoea—Docetaxel—prostate cancer	3.72e-05	0.000199	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—prostate cancer	3.7e-05	0.000198	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—prostate cancer	3.7e-05	0.000198	CcSEcCtD
Pomalidomide—Infection—Epirubicin—prostate cancer	3.64e-05	0.000195	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—prostate cancer	3.63e-05	0.000194	CcSEcCtD
Pomalidomide—Diarrhoea—Capecitabine—prostate cancer	3.6e-05	0.000193	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—prostate cancer	3.59e-05	0.000192	CcSEcCtD
Pomalidomide—Dizziness—Docetaxel—prostate cancer	3.59e-05	0.000192	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—prostate cancer	3.59e-05	0.000192	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—prostate cancer	3.56e-05	0.000191	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—prostate cancer	3.54e-05	0.00019	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—prostate cancer	3.54e-05	0.000189	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—prostate cancer	3.52e-05	0.000189	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.51e-05	0.000188	CcSEcCtD
Pomalidomide—Dizziness—Capecitabine—prostate cancer	3.48e-05	0.000186	CcSEcCtD
Pomalidomide—Vomiting—Docetaxel—prostate cancer	3.45e-05	0.000185	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisone—prostate cancer	3.45e-05	0.000185	CcSEcCtD
Pomalidomide—Rash—Docetaxel—prostate cancer	3.43e-05	0.000183	CcSEcCtD
Pomalidomide—Dermatitis—Docetaxel—prostate cancer	3.42e-05	0.000183	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—prostate cancer	3.42e-05	0.000183	CcSEcCtD
Pomalidomide—Headache—Docetaxel—prostate cancer	3.4e-05	0.000182	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—prostate cancer	3.37e-05	0.00018	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—prostate cancer	3.36e-05	0.00018	CcSEcCtD
Pomalidomide—Vomiting—Capecitabine—prostate cancer	3.34e-05	0.000179	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.34e-05	0.000179	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—prostate cancer	3.33e-05	0.000178	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—prostate cancer	3.32e-05	0.000178	CcSEcCtD
Pomalidomide—Rash—Capecitabine—prostate cancer	3.32e-05	0.000178	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—prostate cancer	3.32e-05	0.000177	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—prostate cancer	3.31e-05	0.000177	CcSEcCtD
Pomalidomide—Dermatitis—Capecitabine—prostate cancer	3.31e-05	0.000177	CcSEcCtD
Pomalidomide—Headache—Capecitabine—prostate cancer	3.3e-05	0.000176	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—prostate cancer	3.29e-05	0.000176	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—prostate cancer	3.28e-05	0.000175	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—prostate cancer	3.27e-05	0.000175	CcSEcCtD
Pomalidomide—Nausea—Docetaxel—prostate cancer	3.23e-05	0.000173	CcSEcCtD
Pomalidomide—Diarrhoea—Prednisone—prostate cancer	3.21e-05	0.000172	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—prostate cancer	3.19e-05	0.00017	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—prostate cancer	3.16e-05	0.000169	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—prostate cancer	3.16e-05	0.000169	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—prostate cancer	3.13e-05	0.000168	CcSEcCtD
Pomalidomide—Pain—Epirubicin—prostate cancer	3.13e-05	0.000168	CcSEcCtD
Pomalidomide—Nausea—Capecitabine—prostate cancer	3.12e-05	0.000167	CcSEcCtD
Pomalidomide—Dizziness—Prednisone—prostate cancer	3.1e-05	0.000166	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.09e-05	0.000165	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—prostate cancer	3.07e-05	0.000164	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—prostate cancer	3.02e-05	0.000162	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—prostate cancer	3.02e-05	0.000162	CcSEcCtD
Pomalidomide—Vomiting—Prednisone—prostate cancer	2.98e-05	0.000159	CcSEcCtD
Pomalidomide—Rash—Prednisone—prostate cancer	2.95e-05	0.000158	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—prostate cancer	2.95e-05	0.000158	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—prostate cancer	2.95e-05	0.000158	CcSEcCtD
Pomalidomide—Headache—Prednisone—prostate cancer	2.94e-05	0.000157	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.93e-05	0.000157	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—prostate cancer	2.92e-05	0.000156	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—prostate cancer	2.9e-05	0.000155	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—prostate cancer	2.9e-05	0.000155	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—prostate cancer	2.9e-05	0.000155	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—prostate cancer	2.79e-05	0.00015	CcSEcCtD
Pomalidomide—Nausea—Prednisone—prostate cancer	2.78e-05	0.000149	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—prostate cancer	2.7e-05	0.000144	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—prostate cancer	2.68e-05	0.000143	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—prostate cancer	2.63e-05	0.000141	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—prostate cancer	2.59e-05	0.000139	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—prostate cancer	2.51e-05	0.000134	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—prostate cancer	2.5e-05	0.000134	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—prostate cancer	2.43e-05	0.00013	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—prostate cancer	2.42e-05	0.00013	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—prostate cancer	2.4e-05	0.000128	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—prostate cancer	2.33e-05	0.000125	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—prostate cancer	2.32e-05	0.000124	CcSEcCtD
Pomalidomide—Rash—Epirubicin—prostate cancer	2.31e-05	0.000124	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—prostate cancer	2.31e-05	0.000124	CcSEcCtD
Pomalidomide—Headache—Epirubicin—prostate cancer	2.3e-05	0.000123	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—prostate cancer	2.24e-05	0.00012	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—prostate cancer	2.18e-05	0.000116	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—prostate cancer	2.16e-05	0.000115	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—prostate cancer	2.14e-05	0.000114	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—prostate cancer	2.14e-05	0.000114	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—prostate cancer	2.12e-05	0.000114	CcSEcCtD
Pomalidomide—Nausea—Doxorubicin—prostate cancer	2.01e-05	0.000108	CcSEcCtD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	5.27e-06	4.64e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOA3—prostate cancer	5.26e-06	4.63e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA2—prostate cancer	5.25e-06	4.63e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NCOA1—prostate cancer	5.22e-06	4.6e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SULT1A1—prostate cancer	5.19e-06	4.57e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCG5—prostate cancer	5.19e-06	4.57e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP19A1—prostate cancer	5.14e-06	4.53e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LPL—prostate cancer	5.13e-06	4.51e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSD17B3—prostate cancer	5.1e-06	4.49e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ACSL4—prostate cancer	5.1e-06	4.49e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRB—prostate cancer	5.08e-06	4.47e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTA1—prostate cancer	5.07e-06	4.46e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—prostate cancer	5.04e-06	4.44e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HPGDS—prostate cancer	5.02e-06	4.42e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTO1—prostate cancer	5.01e-06	4.41e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HSD3B2—prostate cancer	5.01e-06	4.41e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAT2—prostate cancer	5.01e-06	4.41e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2C19—prostate cancer	4.99e-06	4.39e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RXRA—prostate cancer	4.96e-06	4.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERCC2—prostate cancer	4.91e-06	4.32e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ARG2—prostate cancer	4.89e-06	4.31e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UMPS—prostate cancer	4.89e-06	4.31e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PHGDH—prostate cancer	4.89e-06	4.31e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ACHE—prostate cancer	4.87e-06	4.29e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—prostate cancer	4.87e-06	4.29e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.83e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	4.82e-06	4.24e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2A6—prostate cancer	4.81e-06	4.24e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLCB2—prostate cancer	4.8e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2C18—prostate cancer	4.8e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LRP2—prostate cancer	4.8e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB3—prostate cancer	4.8e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LDHB—prostate cancer	4.8e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR2—prostate cancer	4.8e-06	4.22e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—COMT—prostate cancer	4.78e-06	4.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—prostate cancer	4.76e-06	4.19e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	4.72e-06	4.16e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—P4HB—prostate cancer	4.71e-06	4.15e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.71e-06	4.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ITPR1—prostate cancer	4.68e-06	4.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKR1C3—prostate cancer	4.68e-06	4.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PRKACB—prostate cancer	4.66e-06	4.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—prostate cancer	4.62e-06	4.07e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP17A1—prostate cancer	4.61e-06	4.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.61e-06	4.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—prostate cancer	4.6e-06	4.05e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC22A1—prostate cancer	4.58e-06	4.04e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.56e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PDHA1—prostate cancer	4.55e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UCP3—prostate cancer	4.55e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA3—prostate cancer	4.55e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TCN2—prostate cancer	4.55e-06	4.01e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.53e-06	3.99e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SULT2A1—prostate cancer	4.47e-06	3.93e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—prostate cancer	4.42e-06	3.9e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIF1A—prostate cancer	4.4e-06	3.88e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MED12—prostate cancer	4.39e-06	3.87e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOA2—prostate cancer	4.39e-06	3.87e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—prostate cancer	4.37e-06	3.85e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNG5—prostate cancer	4.36e-06	3.84e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.34e-06	3.82e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.34e-06	3.82e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—LPL—prostate cancer	4.29e-06	3.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CAV1—prostate cancer	4.26e-06	3.75e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOA3—prostate cancer	4.2e-06	3.7e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC5A5—prostate cancer	4.19e-06	3.69e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TBXAS1—prostate cancer	4.16e-06	3.66e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA4—prostate cancer	4.16e-06	3.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1A1—prostate cancer	4.15e-06	3.65e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.13e-06	3.63e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ERCC2—prostate cancer	4.11e-06	3.62e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP2E1—prostate cancer	4.09e-06	3.6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA2—prostate cancer	4.05e-06	3.57e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NQO1—prostate cancer	4.05e-06	3.56e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HPGDS—prostate cancer	4.01e-06	3.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCG5—prostate cancer	4e-06	3.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SULT1A1—prostate cancer	4e-06	3.53e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BAD—prostate cancer	4e-06	3.53e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TH—prostate cancer	3.99e-06	3.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2C19—prostate cancer	3.98e-06	3.51e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP3A4—prostate cancer	3.95e-06	3.47e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTA1—prostate cancer	3.91e-06	3.45e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—prostate cancer	3.89e-06	3.42e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ACHE—prostate cancer	3.89e-06	3.42e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1B1—prostate cancer	3.88e-06	3.42e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—prostate cancer	3.88e-06	3.42e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTO1—prostate cancer	3.87e-06	3.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSD3B2—prostate cancer	3.87e-06	3.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAT2—prostate cancer	3.87e-06	3.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—prostate cancer	3.87e-06	3.4e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2A6—prostate cancer	3.84e-06	3.38e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGF—prostate cancer	3.83e-06	3.38e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IRS1—prostate cancer	3.83e-06	3.38e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.83e-06	3.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARA—prostate cancer	3.79e-06	3.34e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GGT1—prostate cancer	3.76e-06	3.31e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKR1C3—prostate cancer	3.74e-06	3.29e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GSK3B—prostate cancer	3.72e-06	3.28e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PRKACB—prostate cancer	3.72e-06	3.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLCB2—prostate cancer	3.71e-06	3.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LRP2—prostate cancer	3.71e-06	3.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.71e-06	3.27e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOA1—prostate cancer	3.7e-06	3.26e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP17A1—prostate cancer	3.68e-06	3.24e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—INS—prostate cancer	3.67e-06	3.23e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP19A1—prostate cancer	3.65e-06	3.21e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—P4HB—prostate cancer	3.64e-06	3.2e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.63e-06	3.2e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREBBP—prostate cancer	3.6e-06	3.17e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CAV1—prostate cancer	3.57e-06	3.14e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.54e-06	3.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RXRA—prostate cancer	3.52e-06	3.1e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOA2—prostate cancer	3.51e-06	3.09e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.45e-06	3.04e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAP2K1—prostate cancer	3.43e-06	3.02e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CD—prostate cancer	3.41e-06	3e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.41e-06	3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MED12—prostate cancer	3.39e-06	2.99e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—COMT—prostate cancer	3.39e-06	2.99e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—prostate cancer	3.37e-06	2.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SERPINE1—prostate cancer	3.37e-06	2.97e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNG5—prostate cancer	3.36e-06	2.96e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC5A5—prostate cancer	3.34e-06	2.94e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ITPR1—prostate cancer	3.32e-06	2.92e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP2E1—prostate cancer	3.27e-06	2.88e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF2—prostate cancer	3.26e-06	2.87e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—prostate cancer	3.25e-06	2.86e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOA3—prostate cancer	3.24e-06	2.85e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NQO1—prostate cancer	3.23e-06	2.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—prostate cancer	3.22e-06	2.84e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TH—prostate cancer	3.18e-06	2.8e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.16e-06	2.79e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP3A4—prostate cancer	3.15e-06	2.77e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—prostate cancer	3.14e-06	2.76e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.13e-06	2.76e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAK2—prostate cancer	3.13e-06	2.76e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—prostate cancer	3.1e-06	2.73e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1B1—prostate cancer	3.1e-06	2.73e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HPGDS—prostate cancer	3.09e-06	2.72e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—INS—prostate cancer	3.07e-06	2.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.07e-06	2.71e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—prostate cancer	3.05e-06	2.69e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LPL—prostate cancer	3.04e-06	2.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CREBBP—prostate cancer	3.01e-06	2.65e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—prostate cancer	3.01e-06	2.65e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—prostate cancer	3e-06	2.64e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ACHE—prostate cancer	3e-06	2.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GGT1—prostate cancer	3e-06	2.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CB—prostate cancer	2.97e-06	2.62e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2A6—prostate cancer	2.96e-06	2.61e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOA1—prostate cancer	2.95e-06	2.6e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1A1—prostate cancer	2.94e-06	2.59e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ERCC2—prostate cancer	2.92e-06	2.57e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP19A1—prostate cancer	2.91e-06	2.56e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKR1C3—prostate cancer	2.88e-06	2.54e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PRKACB—prostate cancer	2.87e-06	2.53e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CD—prostate cancer	2.86e-06	2.51e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.84e-06	2.5e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RXRA—prostate cancer	2.81e-06	2.47e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—prostate cancer	2.79e-06	2.46e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—prostate cancer	2.74e-06	2.41e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.73e-06	2.41e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—COMT—prostate cancer	2.71e-06	2.38e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOA2—prostate cancer	2.71e-06	2.38e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—prostate cancer	2.7e-06	2.37e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—prostate cancer	2.69e-06	2.37e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARA—prostate cancer	2.69e-06	2.37e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ITPR1—prostate cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—prostate cancer	2.63e-06	2.32e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.61e-06	2.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.58e-06	2.27e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—prostate cancer	2.57e-06	2.27e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—prostate cancer	2.57e-06	2.26e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CAV1—prostate cancer	2.53e-06	2.23e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.52e-06	2.22e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—prostate cancer	2.5e-06	2.21e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NQO1—prostate cancer	2.49e-06	2.2e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CB—prostate cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—prostate cancer	2.48e-06	2.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TH—prostate cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—prostate cancer	2.45e-06	2.16e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LPL—prostate cancer	2.43e-06	2.14e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.39e-06	2.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SRC—prostate cancer	2.38e-06	2.1e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.35e-06	2.07e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ERCC2—prostate cancer	2.33e-06	2.05e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GGT1—prostate cancer	2.31e-06	2.04e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—prostate cancer	2.3e-06	2.03e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—prostate cancer	2.3e-06	2.02e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOA1—prostate cancer	2.28e-06	2.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.25e-06	1.98e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—prostate cancer	2.19e-06	1.93e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—INS—prostate cancer	2.18e-06	1.92e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RXRA—prostate cancer	2.17e-06	1.91e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—prostate cancer	2.15e-06	1.89e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARA—prostate cancer	2.15e-06	1.89e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CREBBP—prostate cancer	2.13e-06	1.88e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—prostate cancer	2.13e-06	1.88e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—prostate cancer	2.13e-06	1.87e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—COMT—prostate cancer	2.09e-06	1.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—prostate cancer	2.09e-06	1.84e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—prostate cancer	2.08e-06	1.83e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—prostate cancer	2.05e-06	1.81e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ITPR1—prostate cancer	2.05e-06	1.8e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CD—prostate cancer	2.02e-06	1.78e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CAV1—prostate cancer	2.02e-06	1.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—prostate cancer	1.97e-06	1.74e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—prostate cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—prostate cancer	1.91e-06	1.68e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—prostate cancer	1.91e-06	1.68e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LPL—prostate cancer	1.88e-06	1.65e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.84e-06	1.62e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—prostate cancer	1.81e-06	1.6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.81e-06	1.59e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ERCC2—prostate cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CB—prostate cancer	1.76e-06	1.55e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—prostate cancer	1.75e-06	1.54e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—INS—prostate cancer	1.74e-06	1.53e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CREBBP—prostate cancer	1.7e-06	1.5e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—prostate cancer	1.69e-06	1.49e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARA—prostate cancer	1.66e-06	1.46e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.62e-06	1.42e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—prostate cancer	1.6e-06	1.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CAV1—prostate cancer	1.56e-06	1.37e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—prostate cancer	1.53e-06	1.34e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—prostate cancer	1.52e-06	1.34e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—prostate cancer	1.52e-06	1.34e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—prostate cancer	1.48e-06	1.3e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—prostate cancer	1.45e-06	1.28e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.42e-06	1.25e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.41e-06	1.24e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—prostate cancer	1.4e-06	1.23e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—INS—prostate cancer	1.34e-06	1.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CREBBP—prostate cancer	1.32e-06	1.16e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.25e-06	1.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—prostate cancer	1.24e-06	1.09e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—prostate cancer	1.22e-06	1.07e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—prostate cancer	1.18e-06	1.04e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—prostate cancer	1.16e-06	1.02e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.09e-06	9.57e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—prostate cancer	1.08e-06	9.48e-06	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—prostate cancer	1.08e-06	9.47e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—prostate cancer	9.39e-07	8.27e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—prostate cancer	8.96e-07	7.89e-06	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—prostate cancer	8.79e-07	7.74e-06	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—prostate cancer	8.59e-07	7.56e-06	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—prostate cancer	7.01e-07	6.18e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.63e-07	5.84e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—prostate cancer	5.41e-07	4.77e-06	CbGpPWpGaD
